GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » General and Admin. Expense

CytoDyn (STU:296) General and Admin. Expense : €7.87 Mil (TTM As of Feb. 2025)


View and export this data going back to 2016. Start your Free Trial

What is CytoDyn General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. CytoDyn's General and Admin. Expense for the three months ended in Feb. 2025 was €1.45 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2025 was €7.87 Mil.

CytoDyn General and Admin. Expense Historical Data

The historical data trend for CytoDyn's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn General and Admin. Expense Chart

CytoDyn Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.32 28.25 41.91 15.77 9.98

CytoDyn Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 2.81 1.46 2.16 1.45

CytoDyn General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of CytoDyn's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » General and Admin. Expense
Comparable Companies
PHAT SEPN ITOS XOMA PVLA ATAI ATXS MRVI ATYR AURA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CYDY:USA
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
Website
https://www.cytodyn.com
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines